Gene Fusion Testing Market by Technology (Fluorescence In Situ Hybridization, Immunohistochemistry, Next Generation Sequencing), Sample Type (Blood, Tissue), Application, End User - Global Forecast 2025-2032
Description
The Gene Fusion Testing Market was valued at USD 308.30 million in 2024 and is projected to grow to USD 324.53 million in 2025, with a CAGR of 6.16%, reaching USD 497.39 million by 2032.
Establishing the strategic importance of gene fusion diagnostics through evolving clinical needs, laboratory workflows, and cross-disciplinary integration across healthcare systems
The landscape of gene fusion testing sits at the intersection of molecular biology innovation, clinical demand for precision diagnostics, and evolving laboratory workflows. Advances in assay technologies, coupled with expanding clinical indications across oncology, hematology, and rare diseases, have elevated gene fusion detection from a niche capability to a critical component of diagnostic and therapeutic decision-making. With increasing emphasis on targeted therapies and biomarker-driven treatment strategies, clinicians and laboratories are adopting methods that balance sensitivity, throughput, and cost efficiency while meeting regulatory and reimbursement requirements.
Transitioning from research to routine diagnostics demands robust analytical validation, standardized sample handling, and interoperability between laboratory information systems. Additionally, cross-disciplinary collaboration among pathologists, molecular biologists, and oncologists is accelerating the translation of fusion detection into actionable clinical reports. As technologies mature, stakeholders must navigate an environment shaped by shifting reimbursement policies, evolving clinical guidelines, and the imperative to demonstrate clinical utility. Consequently, organizations that prioritize integrated workflows and evidence generation will be best positioned to influence adoption pathways and to deliver measurable improvements in patient outcomes.
Charting how analytical advances, sample innovation, and cross-sector partnerships are reshaping diagnostic pathways and accelerating clinical integration of fusion testing
Recent years have produced transformative shifts in the gene fusion testing landscape driven by improvements in analytical platforms, expanded clinical indications, and a stronger focus on actionable biomarkers for targeted therapy. Next-generation sequencing platforms have become central to this transition, enabling multidimensional analysis that identifies known and novel fusions while supporting simultaneous detection of other genomic alterations. At the same time, orthogonal technologies such as fluorescence in situ hybridization and immunohistochemistry remain critical for confirmatory testing and rapid triage in resource-constrained settings, creating a complementary testing ecosystem.
Moreover, there has been a noticeable shift in sample management and pre-analytical practices: laboratories increasingly validate assays for plasma-based circulating tumor nucleic acids alongside traditional tissue workflows to support less invasive monitoring. Regulatory pathways and payer expectations are also evolving, prompting laboratories and diagnostic developers to generate real-world evidence and clinical utility studies that demonstrate impact on treatment decisions. As a result, strategic partnerships between diagnostic vendors, pharmaceutical developers, and healthcare providers are becoming more prevalent, accelerating the integration of fusion testing into therapeutic development programs and clinical care.
Assessing how evolving US tariff policies have compelled diagnostic stakeholders to redesign procurement, supplier diversification, and inventory resilience strategies
Recent trade policy changes and tariff implementations in the United States have introduced additional considerations for suppliers, distributors, and clinical laboratories that rely on global supply chains for reagents, instrumentation, and consumables. These policy shifts affect procurement strategies, operational cost structures, and the prioritization of locally sourced versus imported materials. In response, many organizations have re-evaluated supplier diversity and inventory strategies to mitigate the operational impacts of increased customs duties, longer lead times, and the potential for supply interruptions.
Consequently, laboratory managers and diagnostic manufacturers are exploring regional manufacturing capabilities, dual-sourcing arrangements, and strategic inventory buffers to preserve continuity of service. Importantly, procurement teams are increasing focus on total cost of ownership analyses that account for tariff-related expenses, customs handling, and logistics complexity. These adjustments are prompting a broader strategic recalibration: stakeholders are weighing near-term cost mitigation against long-term supply resilience, and are emphasizing transparency in supplier contracts and contingency planning to ensure uninterrupted patient testing and clinical trial operations.
Unpacking how intersecting technology choices, specimen workflows, clinical applications, and end-user models determine adoption priorities and commercialization strategies
A nuanced segmentation approach reveals how technology choices, sample types, clinical applications, and end-user categories shape adoption pathways and value propositions in gene fusion testing. Technology-wise, fluorescence in situ hybridization and immunohistochemistry continue to serve as reliable, established tools for targeted fusion detection and protein expression assessment, while next-generation sequencing dominates for comprehensive molecular profiling; within next-generation sequencing, distinctions between targeted panels, transcriptome sequencing, and whole genome sequencing create gradations of sensitivity, scope, and data complexity that influence assay selection. Reverse transcription polymerase chain reaction remains relevant for high-sensitivity, cost-effective confirmation of specific fusion events, particularly in settings where rapid turnaround is essential.
Sample considerations also influence operational choices: blood-based testing, including plasma and serum workflows, supports minimally invasive diagnostics and longitudinal monitoring, while tissue-based testing, using formalin-fixed paraffin embedded specimens and fresh frozen tissue, often provides the highest confidence for histologic correlation and definitive fusion characterization. Application-driven segmentation further clarifies demand dynamics: hematology settings require workflows optimized for leukemia and lymphoma, oncology programs prioritize panels tailored to breast, colorectal, lung, and prostate cancer, and rare disease investigation demands sensitive assays for developmental and neuromuscular disorder characterization. End-user differentiation underscores how diagnostic laboratories-both hospital-based and independent-operate distinct service models and quality systems compared with hospitals that manage inpatient and outpatient testing; pharmaceutical and biotechnology companies drive assay development and companion diagnostic needs differently than academic centers and private research laboratories focused on discovery and validation. Together, these intersecting segments inform product development, commercialization strategies, and clinical evidence generation priorities for technology providers and laboratory networks.
Analyzing how distinct regulatory, reimbursement, and infrastructure conditions across major global regions dictate tailored market access and deployment strategies
Regional dynamics exert meaningful influence on regulatory requirements, reimbursement pathways, and laboratory infrastructure, shaping where and how gene fusion testing gains traction. The Americas exhibit strong clinical demand driven by consolidated healthcare networks, advanced oncology programs, and active translational research communities; therefore, implementation often emphasizes high-throughput sequencing, streamlined laboratory accreditation, and payer engagement strategies. In contrast, Europe, Middle East & Africa present heterogeneous regulatory environments and varied reimbursement landscapes that require tailored market access approaches, differentiated pricing models, and engagement with national health technology assessment processes to support adoption across diverse healthcare systems. Capacity constraints and variable laboratory infrastructure in parts of the region encourage hybrid testing models that combine centralized reference services with decentralized rapid assays.
Asia-Pacific demonstrates rapid adoption in key urban healthcare hubs where investments in genomics infrastructure, large-scale clinical trials, and public-private partnerships are accelerating uptake. However, differences in sample logistics, language-specific clinical practice patterns, and national regulatory frameworks necessitate localized validation and training programs. Across all regions, strategic considerations include local clinician education, evidence generation aligned to regional treatment guidelines, and partnerships with reference laboratories to ensure quality and scalability. Consequently, stakeholders seeking to expand geographically must design differentiated access strategies that address regulatory, clinical, and operational realities specific to the Americas, Europe, Middle East & Africa, and Asia-Pacific regions.
Highlighting how technology differentiation, strategic partnerships, and post-market evidence strategies determine competitive leadership and long-term sustainability
Competitive dynamics in gene fusion testing favor organizations that combine technological differentiation with rigorous clinical validation and ecosystem partnerships. Leading companies invest in platform scalability, automated workflows, and integrated software solutions that streamline interpretation and reporting; these capabilities reduce time to result and improve consistency across laboratories. Meanwhile, firms that prioritize modular product designs and flexible licensing are better positioned to meet the heterogeneous needs of hospital laboratories, independent reference labs, and research institutions. In addition, companies that align closely with pharmaceutical developers can accelerate the co-development of companion diagnostics and support clinical trials by providing robust assay validation and regulatory support.
Beyond product features, successful companies emphasize post-market evidence generation and customer support, offering education, proficiency testing, and implementation services that reduce the barrier to clinical adoption. Strategic collaborations with academic centers and private research laboratories further enhance credibility and create pathways for joint publications and guideline inclusion. Ultimately, the most resilient companies will be those that pair scientific leadership with operational excellence, clear value demonstration, and a commitment to interoperability and data standards that facilitate integration into clinical workflows and electronic health records.
Recommend a prioritized strategic framework combining assay diversification, clinical evidence programs, and supply chain resilience to accelerate adoption and mitigate risk
Industry leaders should pursue a balanced strategy that integrates technology investment, evidence generation, and supply chain resilience to capture clinical and commercial opportunities in gene fusion testing. Prioritize the development of assay portfolios that span rapid confirmatory methods and comprehensive sequencing, enabling laboratories and clinicians to apply the most appropriate test across diagnostic and monitoring use cases. Simultaneously, invest in standardized protocols for pre-analytics and sample handling to reduce variability and improve concordance between tissue and blood-based assays, which will accelerate clinicians' trust in less invasive testing modalities.
In parallel, cultivate strategic alliances with pharmaceutical developers to co-create companion diagnostics and to support clinical trial programs that embed fusion testing into therapeutic development. Strengthen procurement and manufacturing strategies by diversifying suppliers, exploring regional production partnerships, and building inventory resilience to mitigate tariff and logistics exposure. Finally, commit to transparent value demonstration through well-designed clinical validation studies and real-world evidence initiatives, and support adoption through training, implementation services, and data interoperability solutions that integrate results into clinical decision pathways and electronic medical records.
Detailing a rigorous mixed-methods research approach combining expert interviews, literature synthesis, and cross-validation to support reliable insights for stakeholders
This research synthesizes primary and secondary investigative approaches to deliver a comprehensive analysis of gene fusion testing adoption drivers and operational considerations. Primary inputs included structured interviews with laboratory directors, molecular pathologists, and clinical trial leaders to capture first-hand perspectives on assay selection, throughput requirements, and implementation challenges. These conversations informed thematic analysis around technology trade-offs, sample workflows, and end-user needs. Secondary research reviewed peer-reviewed literature, regulatory guidance documents, and publicly available clinical practice guidelines to contextualize technological capabilities, confirmatory testing strategies, and clinical indications across oncology, hematology, and rare diseases.
To ensure rigor, methodological steps included cross-validation of qualitative insights against documented assay performance metrics and procedural standards, triangulation with manufacturer specifications, and scenario analysis focused on procurement and supply chain variables. Data integrity measures encompassed interview transcription validation, source triangulation, and an audit trail for methodological decisions. Ethical considerations and privacy protections governed the use of interview data, and all clinical claims were corroborated against established guidelines or primary literature. The resulting methodology balances depth of practitioner insight with the objectivity of published evidence to produce actionable findings for commercial, clinical, and operational stakeholders.
Concluding with a synthesis of strategic imperatives that align technological advancement with clinical validation and pragmatic regional deployment to drive adoption
In conclusion, gene fusion testing stands at a pivotal moment where technological maturation, expanding clinical utility, and strategic industry actions can collectively enhance diagnostic precision and therapeutic personalization. Laboratories and diagnostic developers must navigate a complex matrix of technology options, specimen formats, clinical applications, and end-user requirements to design compelling value propositions. Progress will depend on operational excellence in pre-analytical processes, robust clinical validation that demonstrates impact on decision-making, and adaptive commercialization strategies sensitive to regional regulatory and reimbursement nuances.
Moving forward, stakeholders that adopt an integrated approach-linking assay innovation with evidence generation, supply chain resilience, and targeted regional strategies-will be best equipped to translate scientific advances into improved patient pathways. The path to broader clinical adoption requires clear demonstration of utility, practical implementation support for laboratories and clinicians, and sustained collaborations across industry, academic, and clinical communities to ensure that gene fusion testing fulfills its potential to shape precision medicine.
Note: PDF & Excel + Online Access - 1 Year
Establishing the strategic importance of gene fusion diagnostics through evolving clinical needs, laboratory workflows, and cross-disciplinary integration across healthcare systems
The landscape of gene fusion testing sits at the intersection of molecular biology innovation, clinical demand for precision diagnostics, and evolving laboratory workflows. Advances in assay technologies, coupled with expanding clinical indications across oncology, hematology, and rare diseases, have elevated gene fusion detection from a niche capability to a critical component of diagnostic and therapeutic decision-making. With increasing emphasis on targeted therapies and biomarker-driven treatment strategies, clinicians and laboratories are adopting methods that balance sensitivity, throughput, and cost efficiency while meeting regulatory and reimbursement requirements.
Transitioning from research to routine diagnostics demands robust analytical validation, standardized sample handling, and interoperability between laboratory information systems. Additionally, cross-disciplinary collaboration among pathologists, molecular biologists, and oncologists is accelerating the translation of fusion detection into actionable clinical reports. As technologies mature, stakeholders must navigate an environment shaped by shifting reimbursement policies, evolving clinical guidelines, and the imperative to demonstrate clinical utility. Consequently, organizations that prioritize integrated workflows and evidence generation will be best positioned to influence adoption pathways and to deliver measurable improvements in patient outcomes.
Charting how analytical advances, sample innovation, and cross-sector partnerships are reshaping diagnostic pathways and accelerating clinical integration of fusion testing
Recent years have produced transformative shifts in the gene fusion testing landscape driven by improvements in analytical platforms, expanded clinical indications, and a stronger focus on actionable biomarkers for targeted therapy. Next-generation sequencing platforms have become central to this transition, enabling multidimensional analysis that identifies known and novel fusions while supporting simultaneous detection of other genomic alterations. At the same time, orthogonal technologies such as fluorescence in situ hybridization and immunohistochemistry remain critical for confirmatory testing and rapid triage in resource-constrained settings, creating a complementary testing ecosystem.
Moreover, there has been a noticeable shift in sample management and pre-analytical practices: laboratories increasingly validate assays for plasma-based circulating tumor nucleic acids alongside traditional tissue workflows to support less invasive monitoring. Regulatory pathways and payer expectations are also evolving, prompting laboratories and diagnostic developers to generate real-world evidence and clinical utility studies that demonstrate impact on treatment decisions. As a result, strategic partnerships between diagnostic vendors, pharmaceutical developers, and healthcare providers are becoming more prevalent, accelerating the integration of fusion testing into therapeutic development programs and clinical care.
Assessing how evolving US tariff policies have compelled diagnostic stakeholders to redesign procurement, supplier diversification, and inventory resilience strategies
Recent trade policy changes and tariff implementations in the United States have introduced additional considerations for suppliers, distributors, and clinical laboratories that rely on global supply chains for reagents, instrumentation, and consumables. These policy shifts affect procurement strategies, operational cost structures, and the prioritization of locally sourced versus imported materials. In response, many organizations have re-evaluated supplier diversity and inventory strategies to mitigate the operational impacts of increased customs duties, longer lead times, and the potential for supply interruptions.
Consequently, laboratory managers and diagnostic manufacturers are exploring regional manufacturing capabilities, dual-sourcing arrangements, and strategic inventory buffers to preserve continuity of service. Importantly, procurement teams are increasing focus on total cost of ownership analyses that account for tariff-related expenses, customs handling, and logistics complexity. These adjustments are prompting a broader strategic recalibration: stakeholders are weighing near-term cost mitigation against long-term supply resilience, and are emphasizing transparency in supplier contracts and contingency planning to ensure uninterrupted patient testing and clinical trial operations.
Unpacking how intersecting technology choices, specimen workflows, clinical applications, and end-user models determine adoption priorities and commercialization strategies
A nuanced segmentation approach reveals how technology choices, sample types, clinical applications, and end-user categories shape adoption pathways and value propositions in gene fusion testing. Technology-wise, fluorescence in situ hybridization and immunohistochemistry continue to serve as reliable, established tools for targeted fusion detection and protein expression assessment, while next-generation sequencing dominates for comprehensive molecular profiling; within next-generation sequencing, distinctions between targeted panels, transcriptome sequencing, and whole genome sequencing create gradations of sensitivity, scope, and data complexity that influence assay selection. Reverse transcription polymerase chain reaction remains relevant for high-sensitivity, cost-effective confirmation of specific fusion events, particularly in settings where rapid turnaround is essential.
Sample considerations also influence operational choices: blood-based testing, including plasma and serum workflows, supports minimally invasive diagnostics and longitudinal monitoring, while tissue-based testing, using formalin-fixed paraffin embedded specimens and fresh frozen tissue, often provides the highest confidence for histologic correlation and definitive fusion characterization. Application-driven segmentation further clarifies demand dynamics: hematology settings require workflows optimized for leukemia and lymphoma, oncology programs prioritize panels tailored to breast, colorectal, lung, and prostate cancer, and rare disease investigation demands sensitive assays for developmental and neuromuscular disorder characterization. End-user differentiation underscores how diagnostic laboratories-both hospital-based and independent-operate distinct service models and quality systems compared with hospitals that manage inpatient and outpatient testing; pharmaceutical and biotechnology companies drive assay development and companion diagnostic needs differently than academic centers and private research laboratories focused on discovery and validation. Together, these intersecting segments inform product development, commercialization strategies, and clinical evidence generation priorities for technology providers and laboratory networks.
Analyzing how distinct regulatory, reimbursement, and infrastructure conditions across major global regions dictate tailored market access and deployment strategies
Regional dynamics exert meaningful influence on regulatory requirements, reimbursement pathways, and laboratory infrastructure, shaping where and how gene fusion testing gains traction. The Americas exhibit strong clinical demand driven by consolidated healthcare networks, advanced oncology programs, and active translational research communities; therefore, implementation often emphasizes high-throughput sequencing, streamlined laboratory accreditation, and payer engagement strategies. In contrast, Europe, Middle East & Africa present heterogeneous regulatory environments and varied reimbursement landscapes that require tailored market access approaches, differentiated pricing models, and engagement with national health technology assessment processes to support adoption across diverse healthcare systems. Capacity constraints and variable laboratory infrastructure in parts of the region encourage hybrid testing models that combine centralized reference services with decentralized rapid assays.
Asia-Pacific demonstrates rapid adoption in key urban healthcare hubs where investments in genomics infrastructure, large-scale clinical trials, and public-private partnerships are accelerating uptake. However, differences in sample logistics, language-specific clinical practice patterns, and national regulatory frameworks necessitate localized validation and training programs. Across all regions, strategic considerations include local clinician education, evidence generation aligned to regional treatment guidelines, and partnerships with reference laboratories to ensure quality and scalability. Consequently, stakeholders seeking to expand geographically must design differentiated access strategies that address regulatory, clinical, and operational realities specific to the Americas, Europe, Middle East & Africa, and Asia-Pacific regions.
Highlighting how technology differentiation, strategic partnerships, and post-market evidence strategies determine competitive leadership and long-term sustainability
Competitive dynamics in gene fusion testing favor organizations that combine technological differentiation with rigorous clinical validation and ecosystem partnerships. Leading companies invest in platform scalability, automated workflows, and integrated software solutions that streamline interpretation and reporting; these capabilities reduce time to result and improve consistency across laboratories. Meanwhile, firms that prioritize modular product designs and flexible licensing are better positioned to meet the heterogeneous needs of hospital laboratories, independent reference labs, and research institutions. In addition, companies that align closely with pharmaceutical developers can accelerate the co-development of companion diagnostics and support clinical trials by providing robust assay validation and regulatory support.
Beyond product features, successful companies emphasize post-market evidence generation and customer support, offering education, proficiency testing, and implementation services that reduce the barrier to clinical adoption. Strategic collaborations with academic centers and private research laboratories further enhance credibility and create pathways for joint publications and guideline inclusion. Ultimately, the most resilient companies will be those that pair scientific leadership with operational excellence, clear value demonstration, and a commitment to interoperability and data standards that facilitate integration into clinical workflows and electronic health records.
Recommend a prioritized strategic framework combining assay diversification, clinical evidence programs, and supply chain resilience to accelerate adoption and mitigate risk
Industry leaders should pursue a balanced strategy that integrates technology investment, evidence generation, and supply chain resilience to capture clinical and commercial opportunities in gene fusion testing. Prioritize the development of assay portfolios that span rapid confirmatory methods and comprehensive sequencing, enabling laboratories and clinicians to apply the most appropriate test across diagnostic and monitoring use cases. Simultaneously, invest in standardized protocols for pre-analytics and sample handling to reduce variability and improve concordance between tissue and blood-based assays, which will accelerate clinicians' trust in less invasive testing modalities.
In parallel, cultivate strategic alliances with pharmaceutical developers to co-create companion diagnostics and to support clinical trial programs that embed fusion testing into therapeutic development. Strengthen procurement and manufacturing strategies by diversifying suppliers, exploring regional production partnerships, and building inventory resilience to mitigate tariff and logistics exposure. Finally, commit to transparent value demonstration through well-designed clinical validation studies and real-world evidence initiatives, and support adoption through training, implementation services, and data interoperability solutions that integrate results into clinical decision pathways and electronic medical records.
Detailing a rigorous mixed-methods research approach combining expert interviews, literature synthesis, and cross-validation to support reliable insights for stakeholders
This research synthesizes primary and secondary investigative approaches to deliver a comprehensive analysis of gene fusion testing adoption drivers and operational considerations. Primary inputs included structured interviews with laboratory directors, molecular pathologists, and clinical trial leaders to capture first-hand perspectives on assay selection, throughput requirements, and implementation challenges. These conversations informed thematic analysis around technology trade-offs, sample workflows, and end-user needs. Secondary research reviewed peer-reviewed literature, regulatory guidance documents, and publicly available clinical practice guidelines to contextualize technological capabilities, confirmatory testing strategies, and clinical indications across oncology, hematology, and rare diseases.
To ensure rigor, methodological steps included cross-validation of qualitative insights against documented assay performance metrics and procedural standards, triangulation with manufacturer specifications, and scenario analysis focused on procurement and supply chain variables. Data integrity measures encompassed interview transcription validation, source triangulation, and an audit trail for methodological decisions. Ethical considerations and privacy protections governed the use of interview data, and all clinical claims were corroborated against established guidelines or primary literature. The resulting methodology balances depth of practitioner insight with the objectivity of published evidence to produce actionable findings for commercial, clinical, and operational stakeholders.
Concluding with a synthesis of strategic imperatives that align technological advancement with clinical validation and pragmatic regional deployment to drive adoption
In conclusion, gene fusion testing stands at a pivotal moment where technological maturation, expanding clinical utility, and strategic industry actions can collectively enhance diagnostic precision and therapeutic personalization. Laboratories and diagnostic developers must navigate a complex matrix of technology options, specimen formats, clinical applications, and end-user requirements to design compelling value propositions. Progress will depend on operational excellence in pre-analytical processes, robust clinical validation that demonstrates impact on decision-making, and adaptive commercialization strategies sensitive to regional regulatory and reimbursement nuances.
Moving forward, stakeholders that adopt an integrated approach-linking assay innovation with evidence generation, supply chain resilience, and targeted regional strategies-will be best equipped to translate scientific advances into improved patient pathways. The path to broader clinical adoption requires clear demonstration of utility, practical implementation support for laboratories and clinicians, and sustained collaborations across industry, academic, and clinical communities to ensure that gene fusion testing fulfills its potential to shape precision medicine.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
184 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of multiplex next-generation sequencing assays for simultaneous gene fusion detection in oncology patients
- 5.2. Integration of liquid biopsy platforms for noninvasive detection of gene fusions in cancer screening programs
- 5.3. Expansion of targeted therapies driving demand for precise gene fusion profiling in personalized medicine
- 5.4. Development of AI-enabled bioinformatics pipelines to improve gene fusion identification accuracy in clinical diagnostics
- 5.5. Growth of lab-developed tests offering rapid gene fusion analysis for point-of-care oncology decision support
- 5.6. Rising collaborations between diagnostic companies and pharmaceutical firms to co-develop fusion-driven therapeutic biomarkers
- 5.7. Regulatory approvals for novel gene fusion detection kits accelerating market entry across emerging geographies
- 5.8. Increasing utilization of RNA-based multiplex PCR assays for comprehensive detection of rare fusion transcripts in solid tumors
- 5.9. Emergence of automated sample-to-report platforms reducing turnaround time for gene fusion analysis in clinical labs
- 5.10. Investment trends fueling expansion of decentralized testing networks for gene fusion assays in community hospitals
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Gene Fusion Testing Market, by Technology
- 8.1. Fluorescence In Situ Hybridization
- 8.2. Immunohistochemistry
- 8.3. Next Generation Sequencing
- 8.3.1. Targeted Next Generation Sequencing
- 8.3.2. Transcriptome Sequencing
- 8.3.3. Whole Genome Sequencing
- 8.4. Reverse Transcription Polymerase Chain Reaction
- 9. Gene Fusion Testing Market, by Sample Type
- 9.1. Blood
- 9.1.1. Plasma
- 9.1.2. Serum
- 9.2. Tissue
- 9.2.1. Formalin Fixed Paraffin Embedded
- 9.2.2. Fresh Frozen Tissue
- 10. Gene Fusion Testing Market, by Application
- 10.1. Hematology
- 10.1.1. Leukemia
- 10.1.2. Lymphoma
- 10.2. Oncology
- 10.2.1. Breast Cancer
- 10.2.2. Colorectal Cancer
- 10.2.3. Lung Cancer
- 10.2.4. Prostate Cancer
- 10.3. Rare Diseases
- 10.3.1. Developmental Disorders
- 10.3.2. Neuromuscular Disorders
- 11. Gene Fusion Testing Market, by End User
- 11.1. Diagnostic Laboratories
- 11.1.1. Hospital Based Laboratories
- 11.1.2. Independent Laboratories
- 11.2. Hospitals
- 11.2.1. Inpatient Facilities
- 11.2.2. Outpatient Clinics
- 11.3. Pharmaceutical Companies
- 11.3.1. Biotechnology Companies
- 11.3.2. Pharma Giants
- 11.4. Research Institutions
- 11.4.1. Academic Centers
- 11.4.2. Private Research Laboratories
- 12. Gene Fusion Testing Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Gene Fusion Testing Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Gene Fusion Testing Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Amoy Diagnostics Co., Ltd.
- 15.3.2. Integrated DNA Technologies, Inc.
- 15.3.3. Arima Genomics, Inc.
- 15.3.4. Biocartis NV
- 15.3.5. Biocare Medical, LLC
- 15.3.6. F. Hoffmann-La Roche Ltd.
- 15.3.7. Guardant Health, Inc.
- 15.3.8. Illumina, Inc.
- 15.3.9. Myriad Genetics, Inc.
- 15.3.10. Natera, Inc.
- 15.3.11. NeoGenomics, Inc.
- 15.3.12. OncoDNA SA
- 15.3.13. QIAGEN N.V.
- 15.3.14. Quest Diagnostics Incorporated.
- 15.3.15. Thermo Fisher Scientific Inc.
- 15.3.16. Danaher Corporation
- 15.3.17. SOPHiA GENETICS SA
- 15.3.18. Empire Genomics, Inc.
- 15.3.19. Paragon Genomics, Inc.
- 15.3.20. Caris Life Sciences
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
